Louise Cadman
Overview
Explore the profile of Louise Cadman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
609
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cadman L, Reuter C, Jitlal M, Kleeman M, Austin J, Hollingworth T, et al.
Cancer Epidemiol Biomarkers Prev
. 2021 Jan;
30(4):661-668.
PMID: 33514604
Background: Human papillomavirus (HPV)-based screening is rapidly replacing cytology as the cervical screening modality of choice. In addition to being more sensitive than cytology, it can be done on self-collected...
2.
Robles C, Bruni L, Acera A, Riera J, Prats L, Poljak M, et al.
Am J Prev Med
. 2020 Dec;
60(4):478-487.
PMID: 33358719
Introduction: Human papillomavirus-vaccinated cohorts, irrespective of age, will likely reduce their subsequent screening requirements, thus opening opportunities for global cost reduction and program sustainability. The determinants of uptake and completion...
3.
Zelin J, Cadman L, Amara P, Marnoch S, Vosper J
J Fam Plann Reprod Health Care
. 2017 Aug;
43(4):327-330.
PMID: 28780522
No abstract available.
4.
Cuzick J, Cadman L, Ahmad A, Ho L, Terry G, Kleeman M, et al.
Cancer Epidemiol Biomarkers Prev
. 2017 Feb;
26(7):1053-1059.
PMID: 28223432
Human papillomavirus (HPV) testing from clinician-collected cervical and self-collected cervico-vaginal samples is more sensitive for detecting CIN2/CIN3 than cytology-based screening, stimulating interest in HPV testing from urine. The objective was...
5.
Cuzick J, Ahmad A, Austin J, Cadman L, Ho L, Terry G, et al.
J Clin Virol
. 2016 Aug;
82:145-151.
PMID: 27498250
Background: Two transport media, PreservCyt and SurePath, are widely used for cervical cytology screening. There are concerns that they may perform differently for HPV testing. Objectives: A comparison of the...
6.
Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Broeck D, et al.
J Clin Microbiol
. 2016 Jul;
54(9):2337-42.
PMID: 27385707
The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT) studies offer an opportunity to clinically validate HPV assays for use in primary screening for cervical cancer and also provide a...
7.
Lorincz A, Brentnall A, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, et al.
Int J Cancer
. 2016 Jan;
138(11):2745-51.
PMID: 26790008
High-risk human papillomavirus (hrHPV) DNA tests have excellent sensitivity for detection of cervical intraepithelial neoplasia 2 or higher (CIN2+). A drawback of hrHPV screening, however, is modest specificity. Therefore, hrHPV-positive...
8.
Brentnall A, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J, Cuzick J, et al.
Cancer Biomark
. 2015 Sep;
15(5):669-75.
PMID: 26406956
Background: Persistent infection %by with high risk human papillomavirus (hrHPV) types causes cervical cancer but most women who test positive are at very low risk of neoplasia. Strategies are needed...
9.
10.
Cadman L, Wilkes S, Mansour D, Austin J, Ashdown-Barr L, Edwards R, et al.
J Med Screen
. 2014 Nov;
22(1):28-37.
PMID: 25403717
Background: Non-attenders for cervical screening are at increased risk of cervical cancer. Studies offering self-sampling for high-risk Human Papillomavirus (HrHPV) testing have shown greater uptake than sending another invitation for...